Alembic Pharmaceuticals Balans Gezondheid
Financiële gezondheid criteriumcontroles 6/6
Alembic Pharmaceuticals heeft een totaal eigen vermogen van ₹48.2B en een totale schuld van ₹5.1B, wat de schuld-eigenvermogensverhouding op 10.7% brengt. De totale activa en totale passiva bedragen respectievelijk ₹64.5B en ₹16.3B. De EBIT Alembic Pharmaceuticals is ₹7.0B waardoor de rentedekking 13.2 is. Het heeft contanten en kortetermijnbeleggingen van ₹1.2B.
Belangrijke informatie
10.7%
Verhouding schuld/eigen vermogen
₹5.13b
Schuld
| Rente dekkingsratio | 13.2x |
| Contant | ₹1.20b |
| Aandelen | ₹48.18b |
| Totaal verplichtingen | ₹16.27b |
| Totaal activa | ₹64.46b |
Recente financiële gezondheidsupdates
Is Alembic Pharmaceuticals (NSE:APLLTD) Using Too Much Debt?
Sep 03
Alembic Pharmaceuticals (NSE:APLLTD) Seems To Use Debt Rather Sparingly
Jun 03Is Alembic Pharmaceuticals (NSE:APLLTD) A Risky Investment?
Jan 05Here's Why Alembic Pharmaceuticals (NSE:APLLTD) Can Manage Its Debt Responsibly
Sep 27Alembic Pharmaceuticals (NSE:APLLTD) Seems To Use Debt Quite Sensibly
Jun 09Is Alembic Pharmaceuticals (NSE:APLLTD) A Risky Investment?
Feb 22Recent updates
Alembic Pharmaceuticals Limited's (NSE:APLLTD) Intrinsic Value Is Potentially 17% Below Its Share Price
Sep 25Is Alembic Pharmaceuticals (NSE:APLLTD) Using Too Much Debt?
Sep 03Alembic Pharmaceuticals Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Aug 13Market Participants Recognise Alembic Pharmaceuticals Limited's (NSE:APLLTD) Earnings Pushing Shares 25% Higher
Jul 20Alembic Pharmaceuticals (NSE:APLLTD) Seems To Use Debt Rather Sparingly
Jun 03Does This Valuation Of Alembic Pharmaceuticals Limited (NSE:APLLTD) Imply Investors Are Overpaying?
May 11Results: Alembic Pharmaceuticals Limited Exceeded Expectations And The Consensus Has Updated Its Estimates
Feb 08Subdued Growth No Barrier To Alembic Pharmaceuticals Limited (NSE:APLLTD) With Shares Advancing 25%
Jan 21Is Alembic Pharmaceuticals (NSE:APLLTD) A Risky Investment?
Jan 05Here's Why Alembic Pharmaceuticals (NSE:APLLTD) Can Manage Its Debt Responsibly
Sep 27Alembic Pharmaceuticals (NSE:APLLTD) Seems To Use Debt Quite Sensibly
Jun 09A Look At The Fair Value Of Alembic Pharmaceuticals Limited (NSE:APLLTD)
Apr 13Is Alembic Pharmaceuticals (NSE:APLLTD) A Risky Investment?
Feb 22Alembic Pharmaceuticals Limited (NSE:APLLTD) Shares Could Be 21% Below Their Intrinsic Value Estimate
Jan 04We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Alembic Pharmaceuticals Limited's (NSE:APLLTD) CEO For Now
Nov 05Here's Why Alembic Pharmaceuticals (NSE:APLLTD) Has A Meaningful Debt Burden
Aug 10Estimating The Intrinsic Value Of Alembic Pharmaceuticals Limited (NSE:APLLTD)
Jul 20We Think Alembic Pharmaceuticals (NSE:APLLTD) Is Taking Some Risk With Its Debt
May 05Analyse van de financiële positie
Kortlopende schulden: De korte termijn activa ( ₹30.8B ) APLLTD } overtreffen de korte termijn passiva ( ₹14.6B ).
Langlopende schulden: De kortetermijnactiva APLLTD ( ₹30.8B ) overtreffen de langetermijnschulden ( ₹1.7B ).
Schuld/ eigen vermogen geschiedenis en analyse
Schuldniveau: De netto schuld/eigen vermogen ratio ( 8.2% ) APLLTD wordt als voldoende beschouwd.
Schuld verminderen: De schuld/eigen vermogen-ratio van APLLTD is de afgelopen 5 jaar gedaald van 41.5% naar 10.7%.
Schuldendekking: De schuld van APLLTD wordt goed gedekt door de operationele kasstroom ( 156.5% ).
Rentedekking: De rentebetalingen op de schuld van APLLTD worden goed gedekt door EBIT ( 13.2 x dekking).